1. T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

2. Meta-analysis: Diabetes Mellitus and Risk for CV Outcomes

3. T2DM Glucose-Lowering Trials: Intensive Treatment

4. Meta-analysis of Intensive Glycemic Control in T2DM: Major CV Events

5. Meta-analysis of Intensive Glycemic Control in T2DM: CV Endpoints

6. ACCORD Post-hoc Analysis: Effect of Intensive Glycemic Control on IHD

7. ACCORD Post-hoc Analysis: MI and Coronary Revascularization

8. ACCORD Post-hoc Analysis: UA and Composite CV Outcomes

9. Meta-analysis of Intensive Glycemic Control in T2DM: Mortality

10. Intensive Glycemic Control Legacy Effect on CV Outcomes in T2DM

11. UKPDS 10-Year Follow-up: Insulin/SU vs Conventional Therapy*

12. BARI 2D Trial: Study Design

13. BARI 2D: Insulin Sensitization vs Insulin Provision

14. Glucose-Lowering Drugs and CV Outcomes

15. UKPDS 10-Year Follow-up: Metformin vs Conventional Therapy
UKPDS 10-Year Follow-up: Metformin vs Conventional Therapy* in Newly Diagnosed T2DM

16. Glucose-Lowering Drugs and CV Outcomes

17. ORIGIN: Study Design

18. ORIGIN: Composite Outcomes and Their Components

19. Glucose-Lowering Drugs and CV Outcomes

20. EXAMINE: Study Design

21. EXAMINE: Primary Endpoint

22. EXAMINE: CV Death

23. TECOS: Study Design

24. TECOS: Effect of Sitagliptin vs Placebo on the Primary CV Outcome

25. TECOS: Effect of Sitagliptin vs Placebo on the Secondary CV Outcome

26. SAVOR-TIMI 53: Study Design

27. SAVOR-TIMI 53: Effect of Saxagliptin vs Placebo on the Primary CV Outcome

28. SAVOR-TIMI 53: Effect of Saxagliptin vs Placebo on the Secondary CV Outcome

29. ELIXA: Study Design

30. ELIXA: Effect of Lixisenatide vs Placebo on the Primary CV Outcome

31. ELIXA: HF Hospitalization

32. EMPA-REG OUTCOME: Study Design

33. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

34. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

35. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

36. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

37. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-Cause Mortality

38. Explaining the EMPA-REG OUTCOME Findings

39. Explaining the EMPA-REG OUTCOME Findings (cont)

40. Ongoing CV Outcomes Trials in T2DM

41. Summary

42. Summary (cont)

43. Abbreviations

44. Abbreviations (cont)

45. Abbreviations (cont)